Utility of dermatomyositis-specific autoantibodies for diagnosis and clinical subsetting

International Journal of Clinical Rheumatology

Volumn 10, Issue 4, 2015, Pages 257-271

  Sato, Shinji ^a   Kuwana, Masataka ^b  

^a TOKAI UNIVERSITY   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

autoantibodies; clinically amyopathic dermatomyositis; dermatomyositis; dermatomyositis specific antibodies; interstitial lung disease; juvenile dermatomyositis; malignancy; rapidly progressive interstitial lung disease

Indexed keywords

AMINO ACID TRANSFER RNA LIGASE ANTIBODY; ANTINUCLEAR ANTIBODY; ANTINUCLEAR MATRIX PROTEIN 2 ANTIBODY; AUTOANTIBODY; EJ ANTIBODY; HA ANTIBODY; JO 1 ANTIBODY; KS ANTIBODY; KU ANTIBODY; MELANOMA DIFFERENTIATION ASSOCIATED GENE 5 ANTIBODY; MI 2 ANTIBODY; OJ ANTIBODY; PL 12 ANTIBODY; PL 7 ANTIBODY; PM SCL ANTIBODY; SIGNAL RECOGNITION PARTICLE ANTIBODY; SMALL UBIQUITIN LIKE MODIFIER ACTIVATING ENZYME ANTIBODY; TRANSCRIPTION INTERMEDIARY FACTOR 1GAMMA ANTIBODY; U1 RIBONUCLEOPROTEIN ANTIBODY; UNCLASSIFIED DRUG; ZO ANTIBODY;

ANTIBODY DETECTION; ARTHRITIS; CALCINOSIS; CLINICAL FEATURE; DERMATOMYOSITIS; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DYSPHAGIA; FEVER; HUMAN; INTERSTITIAL LUNG DISEASE; JUVENILE DERMATOMYOSITIS; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RASH; REVIEW;

EID: 84944201491     PISSN: 17584272     EISSN: 17584280     Source Type: Journal    
DOI: 10.2217/ijr.15.27     Document Type: Review

References (85)

1. Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology 48, 607-612 (2009
2. Targoff IN. Laboratory testing in the diagnosis and management of idiopathic inflammatory myopathies. Rheum. Dis. Clin. North Am. 28, 859-890 (2002
3. Targoff IN. Myositis specific autoantibodies. Curr. Rheumatol. Rep. 8, 196-203 (2006
4. Nishikai M, Reichlin M. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis: characterization of the Jo-1 antibody system. Arthritis Rheum. 23, 881-888 (1980
5. Hashish L, Trieu EP, Sadanandan P, Targoff IN. Identification of autoantibodies to tyrosyl-TRNA synthetase in dermatomyositis with features consistent with antisynthetase syndrome. Presented at: 2005 ACR/ARHP Annual Meeting. San Diego, CA, USA, 12-17 November 2005.
6. Betteridge ZE, Gunawardena H, North J, Slinn J, McHugh N. Antisynthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology 46, 1005-1008 (2007
7. Hamaguchi Y, Fujimoto M, Matsushita T, et al. Common and distinct clinical features in adult patients with anti-Aminoacyl-TRNA synthetase antibodies: heterogeneity within the syndrome. PLoS ONE 8, e60442 (2013
8. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 70, 360-374 (1991
9. Kaneko Y, Hanaoka H, Hirakata M, Takeuchi T, Kuwana M. Distinct arthropathies of the hands in patients with anti-Aminoacyl tRNA synthetase antibodies: usefulness of autoantibody profiles in classifying patients. Rheumatology 53, 1120-1124 (2014
10. Marie I, Josse S, Hatron PY, et al. Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome. Arthritis Care Res. (Hoboken) 65, 800-808 (2013
11. Kalluri M, Oddis CV. Pulmonary manifestations of the idiopathic inflammatory myopathies. Clin Chest Med. 31, 501-512 (2010
12. Sato S, Hirakata M, Kuwana M, et al. Clinical characteristics of Japanese patients with anti-PL-7 (anti-Threonyl-TRNA synthetase) autoantibodies. Clin. Exp. Rheumatol. 23, 609-615 (2005
13. Yamasaki Y, Yamada H, Nozaki T, et al. Unusually high frequency of autoantibodies to PL-7 associated with milder muscle disease in Japanese patients with polymyositis/ dermatomyositis. Arthritis Rheum. 54, 2004-2009 (2006
14. Rider LG, Shah M, Mamyrova G, et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 92, 223-243 (2013
15. Shah M, Mamyrova G, Targoff IN, et al. The clinical phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore) 92, 25-41 (2013
16. Mathews MB, Bernstein RM. Myositis autoantibody inhibits histidyl-TRNA synthetase: a model for autoimmunity. Nature 304, 177-179 (1983
17. Casciola-Rosen L, Andrade F, Ulanet D, Wong W. B, Rosen A. Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J. Exp. Med. 190, 815-826 (1999
18. Levine SM, Raben N, Xie D, et al. Novel conformation of histidyl-Transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-Associated myositis. Arthritis Rheum. 56, 2729-2739 (2007
19. Casciola-Rosen L, Nagaraju K, Plotz P, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J. Exp. Med. 201, 591-601 (2005
20. Katsumata Y, Ridgway WM, Oriss T, et al. Species-specific immune responses generated by histidyl-TRNA synthetase immunization are associated with muscle and lung inflammation. J. Autoimmun. 29, 174-186 (2007
21. Soejima M, Kang EH, Gu X, Katsumata Y, Clemens PR, Ascherman DP. Role of innate immunity in a murine model of histidyl-Transfer RNA synthetase (Jo-1)-mediated myositis. Arthritis Rheum. 63, 479-487 (2011
22. Eloranta ML, Barbasso Helmers S, Ulfgren AK, Rönnblom L, Alm GV, Lundberg IE. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum. 56, 3112-3124 (2007
23. Stone KB, Oddis CV, Fertig N, et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum. 56, 3125-3131 (2007
24. Targoff IN, Reichlin M. The association between Mi-2 antibodies and dermatomyositis. Arthritis Rheum. 28, 796-803 (1985
25. Zhang Y, LeRoy G, Seelig HP, Lane WS, Reinberg G. The dermatomyositis- specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell 95, 279-289 (1998
26. Wedderburn LR, McHugh NJ, Chinoy H, et al. Juvenile Dermatomyositis Research Group (JDRG). HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap. Rheumatology (Oxford) 46, 1786-1791 (2007
27. Hamaguchi Y, Kuwana M, Hoshino K, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter crosssectional study. Arch. Dermatol. 147, 391-398 (2011
28. Hengstman GJ, Vree Egberts WT, Seelig HP, et al. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann. Rheum. Dis. 65, 242-245 (2006
29. Love LA, Weinberg CR, McConnaughey DR, et al. Ultraviolet radiation intensity predicts the relative distribution of dermatomyositis and anti-Mi-2 autoantibodies in women. Arthritis Rheum. 60, 2499-2504 (2009
30. Burd CJ, Kinyamu HK, Miller FW, Archer TK. UV radiation regulates Mi-2 through protein translation and stability. J. Biol. Chem. 283, 34976-34982 (2008
31. Kashiwagi M, Morgan BA, Georgopoulos K. The chromatin remodeler Mi-2beta is required for establishment of the basal epidermis and normal differentiation of its progeny. Development 134, 1571-1582 (2007
32. Mammen AL, Casciola-Rosen LA, Hall JC, Christopher- Stine L, Corse AM, Rosen A. Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle. Arthritis Rheum. 60, 3784-3793 (2009
33. Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 54, 3682-3689 (2006
34. Kaji K, Fujimoto M, Hasegawa M, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclearproteins in patients with dermatomyositis: an association with malignancy. Rheumatology 46, 25-28 (2007
35. Targoff IN, Trieu EP, Levy-Neto M, Prasertsuntarsai T, Miller FW. Autoantibodies to transcriptional intermediary factor 1-gamma (TIF1-γ) in dermatomyositis. Presented at: 2006 ACR/ARHP Annual Meeting. Washington, DC, USA, 10-15 November 2006.
36. Fujimoto M, Hamaguchi Y, Kaji K, et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum. 64, 513-522 (2012
37. Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-Associated myositis. Ann. Rheum. Dis. 66, 1345-1349 (2007
38. Gunawardena H, Wedderburn LR, North J, et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology 47, 324-328 (2008
39. Trallero-Araguás E, Rodrigo-Pendás JA, Selva-O'Callaghan A, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-Associated dermatomyositis: a systematic review and meta-Analysis. Arthritis Rheum. 64, 523-532 (2012
40. Labrador-Horrillo M, Mart?nez MA, Selva-O'Callaghan A, et al. Anti-TIF1γ antibodies (anti-p155) in adult patients with dermatomyositis: comparison of different diagnostic assays. Ann. Rheum. Dis. 71, 993-996 (2012
41. Petri MH, Satoh M, Martin-Marquez BT, et al. Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara. Arthritis Res. Ther. 15, R48 (2013
42. Fiorentino DF, Chung LS, Christopher-Stine L, et al. Most Patients with Cancer-Associated Dermatomyositis Have Antibodies to Nuclear Matrix Protein NXP-2 or Transcription Intermediary Factor 1γ. Arthritis Rheum. 65, 2954-2962 (2013
43. Cuesta-Mateos C, Colom-Fernandez B, Portero-Sainz I, et al. Autoantibodies against TIF-1-γ and CADM-140 in Spanish patients with clinically amyopathic dermatomyositis (CADM): clinical significance and diagnostic utility. J. Eur. Acad. Dermatol. Venereol. 29, 482-489 (2015
44. Fiorentino DF, Kuo K, Chung L, Zaba L, Li S, Casciola- Rosen L. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J. Am. Acad. Dermatol. 72, 449-455 (2015
45. Yu HH, Chang HM, Chiu CJ, et al. Detection of anti-p155/140, anti-p140, and antiendothelial cells autoantibodies in patients with juvenile dermatomyositis. J. Microbiol. Immunol. Infect. doi:10.1016/j.jmii.2014.05.012 (2014) (Epub ahead of print
46. Satoh M, Chan JY, Ross SJ, et al. Autoantibodies to transcription intermediary factor TIF1β associated with dermatomyositis. Arthritis Res. Ther. 17(14), R79 (2012
47. McNab FW, Rajsbaum R, Stoye JP, O'Garra A. Tripartite-motif proteins and innate immune regulation. Curr. Opin. Immunol. 23, 46-56 (2011
48. Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 52, 1571-1576 (2005
49. Sato S, Hoshino K, Satoh T, et al. RNA helicase encoded by melanoma differentiation-Associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 60, 2193-2200 (2009
50. Nakashima R, Imura Y, Kobayashi S, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford) 49, 433-440 (2010
51. Gono T, Sato S, Kawaguchi Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford) 51, 1563-1570 (2012
52. Tanizawa K, Handa T, Nakashima R, et al. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir. Med. 105, 1380-1387 (2011
53. Cao H, Pan M, Kang Y, et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-MDA5 antibody. Arthritis Care Res. (Hoboken) 64, 1602-1610 (2012
54. Chen Z, Cao M, Plana MN, et al. Utility of anti-melanoma differentiation-Associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-Analysis. Arthritis Care Res. (Hoboken) 65, 1316-1324 (2013
55. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola- Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM- 140): a retrospective study. J. Am. Acad. Dermatol. 65, 25-34 (2011
56. Hall JC, Casciola-Rosen L, Samedy LA, et al. Anti-MDA5- Associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res. (Hoboken) 65, 1307-1315 (2013
57. Moghadam-Kia S, Oddis CV, Sato S, Kuwana M, Aggarwal R. Anti-MDA5 is associated with rapidly-progressive interstitial lung disease and poor survival in U.S. patients with amyopathic and myopathic dermatomyositis. Presented at: 2014 ACR/ARHP Annual Meeting. Boston, MA, USA, 14-19 November 2014.
58. Labrador-Horrillo M, Martinez MA, Selva-O'Callaghan A, et al. Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. J. Immunol. Res. doi:10.1155/2014/290797 (2014) (Epub ahead of print
59. Ceribelli A, Fredi M, Taraborelli M, et al. Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis. Clin. Exp. Rheumatol. 32, 891-897 (2014
60. Chaisson NF, Paik J, Orbai AM, et al. A novel dermato-pulmonary syndrome associated with MDA-5 antibodies: report of 2 cases and review of the literature. Medicine (Baltimore) 91, 220-228 (2012
61. Sato S, Kuwana M, Fujita T, Suzuki Y. Anti-CADM-140/ MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod. Rheumatol. 23, 496-502 (2013
62. Narang NS, Casciola-Rosen L, Li S, Chung L, Fiorentino DF. Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-Associated gene 5 antibodies and interstitial lung disease. Arthritis Care. Res. (Hoboken) 67(5), 667-672 (2014
63. Gono T, Kaneko H, Kawaguchi Y, et al. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology (Oxford) 53, 2196-2203 (2014
64. Gono T, Kawaguchi Y, Kuwana M, et al. Association of HLA-DRB1 0101/ 0405 with susceptibility to anti-melanoma differentiation-Associated gene 5 antibody-positive dermatomyositis in the Japanese population. Arthritis Rheum. 64, 3736-3740 (2012
65. Tansley SL, Betteridge ZE, Gunawardena H, et al. Anti- MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study. Arthritis Res. Ther. 16, R138 (2014
66. Kobayashi N, Takezaki S, Kobayashi I, et al. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology. 54(5), 784-791 (2015
67. Oddis CV, Fertig N, Goel A, et al. Clinical and serological characterization of the anti-MJ antibody in childhood myositis. Arthritis Rheum. 40, S139 (1997
68. Targoff IN, Trieu EP, Levy-Neto M, Fertig N, Oddis CV Sera with Autoantibodies to the MJ Antigen React with NXP2. Arthritis Rheum. 56, S787 (2007)
69. Gunawardena H, Wedderburn LR, Chinoy H, et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum. 60, 1807-1814 (2009
70. Espada G, Maldonado Cocco JA, Fertig N, Oddis CV. Clinical and serologic characterization of an argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J. Rheumatol. 36, 2547-2551 (2009
71. Tansley SL, Betteridge ZE, Shaddick G, et al. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology (Oxford) 53, 2204-2208 (2014
72. Betteridge ZE, Gunawardena H, Chinoy H, et al. Clinical associations of anti-p140 autoantibodies in adult myositis. Ann. Rheum. Dis. 69(Suppl 3), 127 (2010
73. Ceribelli A, Fredi M, Taraborelli M, et al. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res. Ther. 14, R97 (2012
74. Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti- NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann. Rheum. Dis. 71, 710-713 (2012
75. Fiorentino D, Christopher-Stine L, Chung L, et al. Antibodies to NXP-2 and transcriptional intermediary factor-gamma identify patients with cancer-Associated dermatomyositis. Presented at: 2012 ACR/ARHP Annual Meeting. Washington DC, USA, 10-14 November 2012.
76. Betteridge ZE, Gunawardena H, North J, Slinn J, McHugh N. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum. 56, 3132-3137 (2007
77. Betteridge ZE, Gunawardena H, Chinoy H, et al. Clinical and HLA-class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK adult-onset Caucasian myositis. Ann. Rheum. Dis. 68, 1621-1625 (2009
78. Tarricone E, Ghirardello A, Rampudda M, Bassi N, Punzi L, Doria A. Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort. J. Immunolo. Methods 384, 128-134 (2012
79. Fujimoto M, Matsushita T, Hamaguchi Y, et al. Autoantibodies to small ubiquitin-like modifier activating enzymes in Japanese patients with dermatomyositis. Ann. Rheum. Dis. 72, 151-153 (2013
80. Muro Y, Sugiura K, Akiyama M. Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients. Autoimmunity 46, 279-284 (2013
81. Bodoki L, Nagy-Vincze M, Griger Z, Betteridge ZE, Szfllsi L, Danks K. Four dermatomyositis-specific autoantibodies-Anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort. Autoimmun. Rev. 13, 1211-1219 (2014
82. Suzuki S, Hayashi YK, Kuwana M, Tsuburaya R, Suzuki N, Nishino I. Myopathy associated with antibodies to signal recognition particle: disease progression and neurological outcome. Arch. Neurol. 69, 728-732 (2012
83. Mimori T, Hardin JA, Steitz JA. Characterization of the DNA-binding protein antigen Ku recognized by autoantibodies from patients with rheumatic disorders. J. Biol. Chem. 261, 2274-2278 (1986
84. Matucci-Cerinic M, Kveder T. International cohort study of 73 anti-Ku-positive patients: association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis. Arthritis. Res. Ther. 14, R2 (2012
85. D'Aoust J, Hudson M, Tatibouet S, et al. Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients. Arthritis Rheumatol. 66, 1608-1615 (2014